Charles Rhyee
Stock Analyst at TD Cowen
(3.73)
# 1,979
Out of 4,361 analysts
647
Total ratings
49.2%
Success rate
3.4%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COR Cencora | Rated: Buy | $400 | $264.84 | +51.03% | 50 | Jun 1, 2026 | |
| ICLR ICON Public Limited Company | Rated: Buy | $120 → $164 | $137.56 | +19.22% | 19 | Jun 1, 2026 | |
| MDRX Veradigm Inc. | Reiterated: Buy | $8 | $4.50 | +77.78% | 21 | May 27, 2026 | |
| DRIO DarioHealth | Maintained: Hold | $11 | $7.65 | +43.79% | 17 | May 13, 2026 | |
| CVS CVS Health | Reiterated: Buy | $105 → $110 | $89.50 | +22.91% | 58 | May 11, 2026 | |
| EVH Evolent Health | Maintained: Buy | $7 → $8 | $3.96 | +102.02% | 48 | May 11, 2026 | |
| GDRX GoodRx Holdings | Rated: Buy | $3 → $4 | $2.95 | +35.59% | 36 | May 11, 2026 | |
| CRL Charles River Laboratories International | Maintained: Buy | $235 | $174.79 | +34.45% | 21 | May 10, 2026 | |
| MCK McKesson | Reiterated: Buy | $1,012 | $736.78 | +37.35% | 48 | May 7, 2026 | |
| MDLN Medline | Maintained: Buy | $53 | $33.19 | +59.69% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5 → $8 | $8.50 | -5.88% | 20 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $213 | $180.64 | +17.91% | 24 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $18 | $15.36 | +17.19% | 15 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $338 | $272.72 | +23.94% | 18 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 | $7.54 | -20.42% | 58 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $65 | $59.34 | +9.54% | 10 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $20.82 | +101.73% | 9 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $251 → $255 | $194.88 | +30.85% | 38 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $37 → $23 | $20.54 | +11.98% | 6 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $419 | $445.59 | -5.97% | 14 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $380 → $300 | $182.94 | +63.99% | 19 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $9 | $5.22 | +72.41% | 19 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $5.25 | +185.71% | 21 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $24.25 | +271.13% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $72.32 | -29.48% | 1 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.21 | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 | $187.55 | n/a | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.0001 | n/a | 3 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 → $250 | $0.0001 | n/a | 6 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $9 → $1.3 | $0.0001 | n/a | 8 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $370 → $415 | $377.92 | n/a | 6 | Apr 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $360 → $395 | $389.03 | n/a | 5 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $29 | $21.14 | n/a | 1 | Mar 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $74 → $80 | $59.99 | n/a | 4 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $410 → $460 | $320.88 | n/a | 7 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $200 → $210 | $179.86 | n/a | 5 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $30 → $29 | $41.91 | n/a | 4 | Oct 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $18.35 | n/a | 1 | Feb 25, 2014 |
Cencora
Jun 1, 2026
Rated: Buy
Price Target: $400
Current: $264.84
Upside: +51.03%
ICON Public Limited Company
Jun 1, 2026
Rated: Buy
Price Target: $120 → $164
Current: $137.56
Upside: +19.22%
Veradigm Inc.
May 27, 2026
Reiterated: Buy
Price Target: $8
Current: $4.50
Upside: +77.78%
DarioHealth
May 13, 2026
Maintained: Hold
Price Target: $11
Current: $7.65
Upside: +43.79%
CVS Health
May 11, 2026
Reiterated: Buy
Price Target: $105 → $110
Current: $89.50
Upside: +22.91%
Evolent Health
May 11, 2026
Maintained: Buy
Price Target: $7 → $8
Current: $3.96
Upside: +102.02%
GoodRx Holdings
May 11, 2026
Rated: Buy
Price Target: $3 → $4
Current: $2.95
Upside: +35.59%
Charles River Laboratories International
May 10, 2026
Maintained: Buy
Price Target: $235
Current: $174.79
Upside: +34.45%
McKesson
May 7, 2026
Reiterated: Buy
Price Target: $1,012
Current: $736.78
Upside: +37.35%
Medline
May 7, 2026
Maintained: Buy
Price Target: $53
Current: $33.19
Upside: +59.69%
May 6, 2026
Rated: Hold
Price Target: $5 → $8
Current: $8.50
Upside: -5.88%
May 5, 2026
Maintained: Buy
Price Target: $213
Current: $180.64
Upside: +17.91%
May 5, 2026
Rated: Buy
Price Target: $15 → $18
Current: $15.36
Upside: +17.19%
May 4, 2026
Rated: Buy
Price Target: $338
Current: $272.72
Upside: +23.94%
May 4, 2026
Rated: Hold
Price Target: $6
Current: $7.54
Upside: -20.42%
May 4, 2026
Rated: Buy
Price Target: $60 → $65
Current: $59.34
Upside: +9.54%
May 4, 2026
Reiterated: Buy
Price Target: $42
Current: $20.82
Upside: +101.73%
May 1, 2026
Rated: Buy
Price Target: $251 → $255
Current: $194.88
Upside: +30.85%
Apr 30, 2026
Rated: Hold
Price Target: $37 → $23
Current: $20.54
Upside: +11.98%
Apr 23, 2026
Maintained: Hold
Price Target: $419
Current: $445.59
Upside: -5.97%
Mar 5, 2026
Rated: Buy
Price Target: $380 → $300
Current: $182.94
Upside: +63.99%
Feb 20, 2026
Maintained: Buy
Price Target: $6 → $9
Current: $5.22
Upside: +72.41%
Nov 13, 2025
Maintained: Buy
Price Target: $15
Current: $5.25
Upside: +185.71%
Jun 11, 2025
Reiterated: Buy
Price Target: $90
Current: $24.25
Upside: +271.13%
Jun 5, 2025
Initiated Coverage: Buy
Price Target: $51
Current: $72.32
Upside: -29.48%
Sep 9, 2024
Reiterated: Buy
Price Target: n/a
Current: $11.21
Upside: n/a
Oct 30, 2023
Maintained: Buy
Price Target: $170
Current: $187.55
Upside: n/a
Dec 12, 2022
Reiterated: Buy
Price Target: n/a
Current: $0.0001
Upside: n/a
Aug 16, 2022
Maintained: Buy
Price Target: $2 → $250
Current: $0.0001
Upside: n/a
May 17, 2022
Maintained: Sell
Price Target: $9 → $1.3
Current: $0.0001
Upside: n/a
Apr 16, 2021
Maintained: Buy
Price Target: $370 → $415
Current: $377.92
Upside: n/a
Apr 14, 2021
Maintained: Buy
Price Target: $360 → $395
Current: $389.03
Upside: n/a
Mar 29, 2021
Initiated Coverage: Hold
Price Target: $29
Current: $21.14
Upside: n/a
Feb 8, 2021
Maintained: Buy
Price Target: $74 → $80
Current: $59.99
Upside: n/a
Feb 1, 2021
Maintained: Hold
Price Target: $410 → $460
Current: $320.88
Upside: n/a
Jun 16, 2020
Upgraded: Buy
Price Target: $200 → $210
Current: $179.86
Upside: n/a
Oct 30, 2015
Maintained: Hold
Price Target: $30 → $29
Current: $41.91
Upside: n/a
Feb 25, 2014
Initiated Coverage: Buy
Price Target: $42
Current: $18.35
Upside: n/a